Gilead Sciences, Inc. (GILD) Shares Sold by BDO Wealth Advisors LLC

BDO Wealth Advisors LLC cut its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 28.4% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,908 shares of the biopharmaceutical company’s stock after selling 756 shares during the quarter. BDO Wealth Advisors LLC’s holdings in Gilead Sciences were worth $119,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Paloma Partners Management Co bought a new stake in shares of Gilead Sciences during the 4th quarter worth approximately $1,465,000. Candriam Luxembourg S.C.A. increased its position in Gilead Sciences by 17.5% in the 4th quarter. Candriam Luxembourg S.C.A. now owns 1,573,913 shares of the biopharmaceutical company’s stock valued at $98,444,000 after acquiring an additional 234,620 shares during the period. Squarepoint Ops LLC acquired a new position in Gilead Sciences in the 4th quarter valued at approximately $30,069,000. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp increased its position in shares of Gilead Sciences by 95.7% during the fourth quarter. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp now owns 554,083 shares of the biopharmaceutical company’s stock worth $34,658,000 after buying an additional 271,000 shares during the period. Finally, Orbimed Advisors LLC increased its position in shares of Gilead Sciences by 21.7% during the fourth quarter. Orbimed Advisors LLC now owns 443,800 shares of the biopharmaceutical company’s stock worth $27,760,000 after buying an additional 79,200 shares during the period. Institutional investors and hedge funds own 80.20% of the company’s stock.

In other Gilead Sciences news, Director John Francis Cogan sold 2,700 shares of Gilead Sciences stock in a transaction that occurred on Wednesday, March 20th. The shares were sold at an average price of $65.07, for a total transaction of $175,689.00. Following the completion of the sale, the director now directly owns 57,560 shares in the company, valued at $3,745,429.20. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Richard James Whitley sold 9,534 shares of Gilead Sciences stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $65.48, for a total transaction of $624,286.32. Following the sale, the director now owns 34,669 shares of the company’s stock, valued at $2,270,126.12. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 42,102 shares of company stock valued at $2,787,375. 0.20% of the stock is owned by corporate insiders.

Several research firms have recently weighed in on GILD. Zacks Investment Research upgraded shares of Gilead Sciences from a “sell” rating to a “hold” rating in a research report on Tuesday, April 9th. Oppenheimer set a $85.00 price objective on shares of Gilead Sciences and gave the stock a “buy” rating in a research report on Tuesday, March 19th. Maxim Group reiterated a “buy” rating and set a $84.00 price objective on shares of Gilead Sciences in a research report on Friday, March 29th. Mizuho set a $88.00 price objective on shares of Gilead Sciences and gave the stock a “buy” rating in a research report on Friday, April 12th. Finally, UBS Group upgraded shares of Gilead Sciences from a “neutral” rating to a “buy” rating and raised their price target for the stock from $75.00 to $77.00 in a report on Wednesday, April 10th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company’s stock. Gilead Sciences presently has an average rating of “Buy” and a consensus price target of $82.12.

GILD stock traded down $0.30 during mid-day trading on Friday, hitting $62.95. The company had a trading volume of 11,552,923 shares, compared to its average volume of 6,643,269. The firm has a market cap of $80.29 billion, a price-to-earnings ratio of 10.24, a P/E/G ratio of 4.19 and a beta of 1.16. The company has a debt-to-equity ratio of 1.19, a quick ratio of 3.30 and a current ratio of 3.38. Gilead Sciences, Inc. has a 12 month low of $60.32 and a 12 month high of $79.61.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Monday, February 4th. The biopharmaceutical company reported $1.44 earnings per share for the quarter, missing the consensus estimate of $1.70 by ($0.26). The business had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.52 billion. Gilead Sciences had a return on equity of 37.03% and a net margin of 24.65%. Gilead Sciences’s revenue for the quarter was down 2.6% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.78 EPS. Analysts forecast that Gilead Sciences, Inc. will post 6.23 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 28th. Investors of record on Friday, March 15th were paid a dividend of $0.63 per share. The ex-dividend date was Thursday, March 14th. This represents a $2.52 annualized dividend and a yield of 4.00%. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.57. Gilead Sciences’s payout ratio is currently 40.98%.

COPYRIGHT VIOLATION NOTICE: This article was published by Baseball Daily News and is owned by of Baseball Daily News. If you are reading this article on another website, it was stolen and reposted in violation of international trademark and copyright laws. The correct version of this article can be accessed at https://www.baseballdailydigest.com/news/2019/04/21/gilead-sciences-inc-gild-holdings-reduced-by-bdo-wealth-advisors-llc.html.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. Its primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.

Read More: Resistance Level

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.